All In Biotech

Drug Trial Radar · NCT06049147

Study to Assess the Safety and Tolerability of MBF-015 in Healthy Young Volunteers

Randomized, Double Blind, Placebo Controlled "First-in-human" Study to Assess the Safety and Tolerability of Single Ascending Oral Doses and Multiple Oral Doses of MBF-015 in Healthy Young Volunteers

Last checked: Nov 19, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Jul 7, 2021

Primary completion

Aug 24, 2023

Study completion Aug 24, 2023

Sponsor

Lead sponsor
Medibiofarma S.L.Industry
Sponsor type
Industry
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single center, randomised, double blind, placebo controlled clinical study to assess the safety and tolerability of MBF-015 in healthy volunteers.This clinical phase I trial is divided in two stages and involves, first, a single ascending dose (SAD) study in healthy young male volunteers and then a multiple ascending dose (MAD) study in healthy young men and woman. MBF-118 is developed for the treatment of multiple sclerosis.

Conditions

  • Safety and Pharmacokinetic

Interventions

  • MBF-015 4 mg oral capsuleDrug

    MBF-015 oral capsules Histone deacetylase inhibitor

  • MBF-015 16 mg oral capsuleDrug

    MBF-015 oral capsules Histone deacetylase inhibitor

  • PlaceboDrug

    Hard gelatin capsules filled with cellulose microcrystalline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse eventsTime frame: Day 1 through Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CIM-Sant Pau Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.